Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have received an average recommendation of “Buy” from the eight ratings firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and two have issued a strong buy recommendation on the company.

A number of research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a “hold” rating to a “buy” rating in a research note on Thursday, July 2nd. Zacks Research raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 10th. Jefferies Financial Group upgraded Bayer Aktiengesellschaft to a “hold” rating in a report on Friday, May 29th. Finally, DZ Bank raised Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th.

Bayer Aktiengesellschaft Trading Up 0.9%

BAYRY opened at $14.35 on Friday. The firm has a 50 day simple moving average of $13.99 and a 200 day simple moving average of $12.23. Bayer Aktiengesellschaft has a fifty-two week low of $7.48 and a fifty-two week high of $15.23. The company has a market cap of $56.38 billion, a price-to-earnings ratio of -28.13, a price-to-earnings-growth ratio of 4.46 and a beta of 0.56. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.05 and a quick ratio of 0.70.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 17.00%. The firm had revenue of $12.53 billion for the quarter, compared to analysts’ expectations of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. On average, sell-side analysts anticipate that Bayer Aktiengesellschaft will post 1.28 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.